Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 27, 2026 17:37 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

A 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years (n=5) receiving icovamenib 200 mg, with a clear dose response observed vs 100 mg (n=6)Persistence...
April 27, 2026 17:13 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both...
April 27, 2026 17:00 ET | Source: Arbor Biotechnologies Inc

Arbor Biotechnologies to Present Expansion of CNS Editing Platform Capabilities at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting

- Oral presentation highlights novel compact RT editor demonstrating first preclinical in vivo proof of concept for precise gene editing in the CNS delivered via a single AAV - Poster presentations...
April 27, 2026 16:34 ET | Source: Dyne Therapeutics, Inc.

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

- Data underscore the differentiated capability of the clinically validated FORCE platform to cross the blood-brain barrier - WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics,...
April 27, 2026 16:30 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma Announces Unveiling of UB-VV500 in Upcoming Poster Presentation at the American Society of Gene & Cell Therapy Annual Meeting

- Industry’s First Combination BCMA x GPRC5D In Vivo CAR T Cell Therapy for the Treatment of Multiple Myeloma - SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a...
April 27, 2026 16:03 ET | Source: NurExone Biologic Inc

Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production

TORONTO, Ontario and HAIFA, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company...
April 27, 2026 16:01 ET | Source: Erasca, Inc.

Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L...
April 27, 2026 14:30 ET | Source: Pinnacle Treatment Centers

Aegis Treatment Centers Opens Medication Unit in Crescent City, Expanding Access to Addiction Treatment in Del Norte County

Crescent City, CA, April 27, 2026 (GLOBE NEWSWIRE) -- Crescent City, California – 4/24/2026 Aegis Treatment Centers, part of the Pinnacle Treatment Centers family of companies, today announced...
April 27, 2026 13:36 ET | Source: BCC Research LLC

AI Disruption in Lung Cancer Therapeutics Set to Transform Treatment Paradigms as Billion-Dollar Investments Drive Innovation

With AI tools demonstrating 85–95% accuracy in biomarker identification and attracting more than $3 billion in recent funding.
April 27, 2026 12:43 ET | Source: Global Virus Network

Global Virus Network Statement on H5N1 Vaccine Developments

The Global Virus Network underscores the continued threat of H5N1 and calls for sustained global vigilance, surveillance, and preparedness.